Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 234

1.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H.

J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

2.

Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes.

Houghton D, Hardy T, Stewart C, Errington L, Day CP, Trenell MI, Avery L.

Diabetologia. 2018 May 12. doi: 10.1007/s00125-018-4632-0. [Epub ahead of print] Review.

3.

A direct link between MITF, innate immunity, and hair graying.

Harris ML, Fufa TD, Palmer JW, Joshi SS, Larson DM, Incao A, Gildea DE, Trivedi NS, Lee AN, Day CP, Michael HT, Hornyak TJ, Merlino G; NISC Comparative Sequencing Program, Pavan WJ.

PLoS Biol. 2018 May 3;16(5):e2003648. doi: 10.1371/journal.pbio.2003648. eCollection 2018 May.

4.

Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

Whitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, Eyer F, Gleeson D, Thompson A, Stickel F, Soyka M, Daly AK, Cordell HJ, Liang T, Foroud T, Lumeng L, Pirmohamed M, Nalpas B, Bence C, Jacquet JM, Louvet A, Moirand R, Nahon P, Naveau S, Perney P, Podevin P, Haber PS, Seitz HK, Day CP, Mathurin P, Morgan TM, Seth D; GenomALC Consortium.

Alcohol. 2018 Feb;66:1-7. doi: 10.1016/j.alcohol.2017.07.006. Epub 2017 Sep 23.

PMID:
29277282
5.

Identification of essential genes for cancer immunotherapy.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.

Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.

6.

Cellular senescence drives age-dependent hepatic steatosis.

Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, Grellscheid SN, Hoeijmakers JHJ, Barnhoorn S, Mann DA, Bird TG, Vermeij WP, Kirkland JL, Passos JF, von Zglinicki T, Jurk D.

Nat Commun. 2017 Jun 13;8:15691. doi: 10.1038/ncomms15691.

7.

Genetically engineered mouse models of melanoma.

Pérez-Guijarro E, Day CP, Merlino G, Zaidi MR.

Cancer. 2017 Jun 1;123(S11):2089-2103. doi: 10.1002/cncr.30684. Review.

8.

Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers.

Houghton D, Hallsworth K, Thoma C, Cassidy S, Hardy T, Heaps S, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Trenell MI.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1596-1603.e3. doi: 10.1016/j.cgh.2017.05.001. Epub 2017 May 10.

PMID:
28501537
9.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP.

PLoS One. 2017 Apr 18;12(4):e0175717. doi: 10.1371/journal.pone.0175717. eCollection 2017.

10.

Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance.

Day CP, Marchalik R, Merlino G, Michael H.

Lab Invest. 2017 Jun;97(6):698-705. doi: 10.1038/labinvest.2016.155. Epub 2017 Jan 16. Review.

11.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

12.

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.

Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, McPherson S, Anstee QM, Trenell MI.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3. doi: 10.1016/j.cgh.2016.07.031. Epub 2016 Aug 10.

13.

Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.

Liu W, Anstee QM, Wang X, Gawrieh S, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, Daly AK, Day CP, Chalasani N.

Aging (Albany NY). 2016 Oct 13;9(1):26-40. doi: 10.18632/aging.101067.

14.

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.

McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM.

Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11.

15.

Concepts in Cancer Modeling: A Brief History.

Thomas RM, Van Dyke T, Merlino G, Day CP.

Cancer Res. 2016 Oct 15;76(20):5921-5925. Epub 2016 Sep 30. Review.

16.

How to Diagnose Nonalcoholic Fatty Liver Disease.

de Alwis NM, Anstee QM, Day CP.

Dig Dis. 2016;34 Suppl 1:19-26. doi: 10.1159/000447277. Epub 2016 Aug 22.

PMID:
27547937
17.

Gut Microbiota and Lifestyle Interventions in NAFLD.

Houghton D, Stewart CJ, Day CP, Trenell M.

Int J Mol Sci. 2016 Mar 25;17(4):447. doi: 10.3390/ijms17040447. Review.

18.

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.

Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, Henderson E, Tiniakos D, White S, French J, Mann DA, Anstee QM, Mann J.

Gut. 2017 Jul;66(7):1321-1328. doi: 10.1136/gutjnl-2016-311526. Epub 2016 Mar 21.

19.

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

Hardy T, Oakley F, Anstee QM, Day CP.

Annu Rev Pathol. 2016 May 23;11:451-96. doi: 10.1146/annurev-pathol-012615-044224. Epub 2016 Mar 3. Review.

PMID:
26980160
20.

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Reeves HL, Zaki MY, Day CP.

Dig Dis Sci. 2016 May;61(5):1234-45. doi: 10.1007/s10620-016-4085-6. Epub 2016 Feb 26. Review.

PMID:
26921078

Supplemental Content

Support Center